SEA
26/01/2016 13:26
GENERAL
NOT PRICE SENSITIVE
REL: 1326 HRS SeaDragon Limited
GENERAL: SEA: Directors sell shares on undertakings to Takeovers Panel
NZX / MEDIA RELEASE 26
January 2016
Directors sell shares on undertakings to Takeovers Panel
SeaDragon Limited (NZX:SEA) has received a number of enquiries from
shareholders regarding the sale of relatively small parcels of shares by
entities associated with Ross Keeley (former CEO and former director) and
Stuart Macintosh (current director). SeaDragon is not involved in those
transactions. Mr Keeley and Mr Macintosh have advised the company that the
Takeovers Panel has required the sale of approximately 7.8 million shares
that were acquired in the rights offer process completed late last year, due
to an inadvertent breach of the Takeovers Code. Mr Keeley has also advised
the company that he has sold a small number of SeaDragon shares to realise
cash to invest in his other business interests.
Both Mr Keeley and Mr Macintosh have confirmed their on-going commitment to
SeaDragon and they have advised that they will both retain ownership
interests in SeaDragon following these share sales. Any further enquiries
regarding these transactions should be directed to either Mr Keeley or Mr
Macintosh rather than to SeaDragon.
For further information contact:
Colin Groves
Chairman
Tel: +64 21 928 003
About SeaDragon www.seadragon.co.nz
SeaDragon (NZX:SEA) is New Zealand's largest refiner and blender of
high-quality, internationally-certified concentrated fish oils and fractions,
including Omega-3 oils. Our oils are sourced from fish caught in the clean
and pure waters around New Zealand, in the Southern Ocean, and elsewhere. We
have more than 20 years' experience processing fish oils and we are
recognised for the quality and purity of our products. We supply health
supplement manufacturers around the world to meet the burgeoning demand for
pure, high-quality fish oils, which are scientifically proven to deliver
significant human health benefits such as lowering the risk of heart disease,
improving brain function and joint health. The majority of our supply is
exported.
End CA:00276825 For:SEA Type:GENERAL Time:2016-01-26 13:26:31
